Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.79 |
| ▸ | TNK2 | Q07912 | 15/20 | 0.63 |
| ▸ | INSR | P06213 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399400 | 0.89 | IGF1R (1.00) | IGF1RTNK2INSRCYP3A4 | |
| SCHEMBL399075 | 0.85 | IGF1R (0.77) | IGF1RTNK2INSRCYP3A4 | |
| SCHEMBL8240001 | 0.84 | TNK2 (0.83) | IGF1RTNK2 | |
| SCHEMBL400602 | 0.83 | IGF1R (0.79) | IGF1RTNK2CYP3A4 | |
| SCHEMBL10225869 | 0.82 | IGF1R (0.69) | IGF1RTNK2INSR | |
| Carbamic Acid SCHEMBL4070437 | 0.82 | IGF1R (0.86) | IGF1RTNK2INSRCYP3A4 | |
| SCHEMBL402179 | 0.80 | IGF1R (0.81) | IGF1RTNK2INSRCYP3A4 | |
| SCHEMBL10273844 | 0.79 | IGF1R (0.65) | IGF1RTNK2INSR | |
| SCHEMBL4073360 | 0.79 | IGF1R (0.81) | IGF1RTNK2INSRCYP3A4 | |
| SCHEMBL400022 | 0.79 | IGF1R (0.81) | IGF1RTNK2INSRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | IGF1R 1/4885TNK2 405/4885INSR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.